Abstract

Mislocalization of the predominantly nuclear RNA/DNA binding protein, TDP-43, occurs in motor neurons of ~95% of amyotrophic lateral sclerosis (ALS) patients, but the contribution of axonal TDP-43 to this neurodegenerative disease is unclear. Here, we show TDP-43 accumulation in intra-muscular nerves from ALS patients and in axons of human iPSC-derived motor neurons of ALS patient, as well as in motor neurons and neuromuscular junctions (NMJs) of a TDP-43 mislocalization mouse model. In axons, TDP-43 is hyper-phosphorylated and promotes G3BP1-positive ribonucleoprotein (RNP) condensate assembly, consequently inhibiting local protein synthesis in distal axons and NMJs. Specifically, the axonal and synaptic levels of nuclear-encoded mitochondrial proteins are reduced. Clearance of axonal TDP-43 or dissociation of G3BP1 condensates restored local translation and resolved TDP-43-derived toxicity in both axons and NMJs. These findings support an axonal gain of function of TDP-43 in ALS, which can be targeted for therapeutic development.

Here, the authors show in human iPSC-derived motor neurons from ALS patients and a TDP-43 mouse model that axonal TDP-43 forms G3BP1 positive RNP condensates, which sequester mRNA of nuclear encoded mitochondrial proteins and decrease local protein synthesis in motor neuron axons and neuromuscular junctions.

Details

Title
Axonal TDP-43 condensates drive neuromuscular junction disruption through inhibition of local synthesis of nuclear encoded mitochondrial proteins
Author
Altman Topaz 1 ; Ionescu Ariel 1 ; Ibraheem Amjad 1 ; Priesmann Dominik 2   VIAFID ORCID Logo  ; Tal, Gradus-Pery 1 ; Farberov Luba 1 ; Gayster, Alexandra 3 ; Shelestovich Natalia 3 ; Dafinca Ruxandra 4   VIAFID ORCID Logo  ; Shomron Noam 5 ; Rage Florence 6   VIAFID ORCID Logo  ; Talbot, Kevin 4   VIAFID ORCID Logo  ; Ward, Michael E 7 ; Dori, Amir 8   VIAFID ORCID Logo  ; Krüger, Marcus 2   VIAFID ORCID Logo  ; Perlson Eran 5   VIAFID ORCID Logo 

 Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel (GRID:grid.12136.37) (ISNI:0000 0004 1937 0546) 
 CECAD Research Center and Center for Molecular Medicine (CMMC), University of Cologne, Cologne, Germany (GRID:grid.6190.e) (ISNI:0000 0000 8580 3777) 
 Pathology Institute, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel (GRID:grid.413795.d) (ISNI:0000 0001 2107 2845) 
 University of Oxford, Nuffield Department of Clinical Neurosciences, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948) 
 Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel (GRID:grid.12136.37) (ISNI:0000 0004 1937 0546); Sagol School of Neuroscience, Tel-Aviv University, Tel-Aviv, Israel (GRID:grid.12136.37) (ISNI:0000 0004 1937 0546) 
 Institut de Génétique Moléculaire de Montpellier, Montpellier, France (GRID:grid.429192.5) (ISNI:0000 0004 0599 0285) 
 National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, USA (GRID:grid.416870.c) (ISNI:0000 0001 2177 357X) 
 Tel Hashomer and Sackler Faculty of Medicine, Tel Aviv University, Department of Neurology, Sheba Medical Center, Ramat Gan, Israel (GRID:grid.12136.37) (ISNI:0000 0004 1937 0546) 
Publication year
2021
Publication date
2021
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2602346008
Copyright
© The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.